Compare CDLX & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | BMRA |
|---|---|---|
| Founded | 2008 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.5M |
| IPO Year | 2018 | 1995 |
| Metric | CDLX | BMRA |
|---|---|---|
| Price | $1.34 | $1.35 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.43 | N/A |
| AVG Volume (30 Days) | ★ 67.3K | 9.8K |
| Earning Date | 11-05-2026 | 10-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | $4,453,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $1.27 |
| 52 Week High | $6.40 | $2.94 |
| Indicator | CDLX | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 28.35 | 28.69 |
| Support Level | $0.85 | N/A |
| Resistance Level | $2.32 | $1.75 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 2.02 | 15.38 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.